Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis

NCT04305145 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04305145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04305145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 31, 2020
Completion date
June 30, 2030
Enrollment
42 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

drug toxicity, drug-induced colitis, immune-related adverse event, melanoma stage iii, melanoma stage iv, skin cancer stage iii, skin cancer stage iv